Arbor Biotechnologies, Inc.
790 Memorial Drive
About Arbor Biotechnologies, Inc.YEAR FOUNDED:
Founders: Feng Zhang, David Walt, Winston Yan, Keith Crandell and Annie Hazlehurst
26 articles with Arbor Biotechnologies, Inc.
Arbor Biotechnologies today announced its participation in the upcoming Bank of America Global Healthcare Conference in Las Vegas, NV.
Arbor Biotechnologies Announces Presentations at 2022 Annual Meeting of the American Society of Gene & Cell Therapy
Arbor Biotechnologies announced upcoming preclinical data presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy being held May 16-19, 2022, in Washington, D.C.
Arbor Biotechnologies today announced the appointment of Steven J. Favaloro as Chief Financial Officer.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs
EdiGene, Inc. announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, to access Arbor’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.
Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
TCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies
TCR2 Therapeutics Inc. (Nasdaq: TCRR), and Arbor Biotechnologies, today announced that the two companies have entered into a strategic research collaboration and non-exclusive license agreement focused on the further development of a defined set of allogeneic TRuC-T cell therapies.
11/10/2021Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here's who snagged funding this week.
Arbor announced an oversubscribed Series B raise totaling $215 million, a significant increase from their initial $15.6 milllion Series A round to test for liver and CNS diseases.
Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics
Arbor Biotechnologies today announced the completion of an oversubscribed and up-sized $215 million Series B financing.
With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.
Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
Vertex Pharmaceuticals Incorporated and Arbor Biotechnologies announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor’s proprietary CRISPR gene-editing technology for select diseases.
Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced the appointments of Pam Stetkiewicz, Ph.D., as Chief Operating Officer, and Kathryn McCabe, Ph.D., as SVP, Head of Business Development.
Arbor Biotechnologies announced today that it will present at the Raymond James Human Health Innovation Conference at 2 p.m. ET on Tuesday, June 22, 2021, as one of a select group of companies invited to present.
Arbor Biotechnologies to Present at the Evercore ISI GenomeRx Emerging Therapeutics Conference and the Jefferies Virtual Healthcare Conference
Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced that it will present at two upcoming virtual investor conferences
Arbor Continues to Build Therapeutic Focus with Key Scientific LeadersJohn Murphy, Ph.D., named Chief Scientific Officer and Greg Hoffman, Ph.D., joins as VP, Discovery & Platform
Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced today that John Murphy, Ph.D., has joined as Chief Scientific Officer and Greg Hoffman, Ph.D., has joined as Vice President, Discovery & Platform
Arbor Biotechnologies, an early-stage life sciences company unlocking nature’s genetic diversity to enable revolutionary gene editing capabilities, today announced it has appointed Devyn M. Smith, Ph.D., as Chief Executive Officer.
Arbor Biotechnologies announced today the appointment of Mark D. Angelino, co-founder and former Chief Operating Officer of Generation Bio, to its Board of Directors. Mark brings significant company building and product development experience to the Arbor Board, given his expertise over the past 20 years working with numerous leading pharmaceutical companies.
The new agreement will provide Lonza with access to Arbor’s gene editing technology Quote from David Cheng, CEO of Arbor: “Arbor's differentiated gene editing technologies allow Lonza to manufacture the next generation of therapeutics. Arbor is committed to seeking and working with partners in this field to build an ecosystem for the research, development and manufacturing of biological and cellular therapies.”
Vor Biopharma and Arbor Biotechnologies to Collaborate on Engineered Hematopoietic Stem-Cell Therapies
Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and Arbor Biotechnologies, an early-stage life sciences company, today announced an agreement to use Arbor’s gene editing technologies to engineer hematopoietic stem cells, towards the goal of developing therapies for the treatment of blood cancers, such as acute myeloid leukemia. "At Vor, we ar